Vitamin A and COVID-19
Phase 3
Recruiting
- Conditions
- Covid-19.
- Registration Number
- IRCT20200405046951N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Being at the age of 18-80 years old
The same treatment protocol
Desire to participate in project
Exclusion Criteria
Severe liver and biliary disease and known pancreatitis
History of vitamin A supplementation last month
Pregnancy
Lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Weaning time of ventilator. Timepoint: Before and after of intervention. Method of measurement: time assessment.
- Secondary Outcome Measures
Name Time Method Rapid shallow breathing index (RSBI). Timepoint: before and after intervention. Method of measurement: ventilator.;Pao2/Fio2 ratio. Timepoint: before and after intervention. Method of measurement: ventilator.;Fraction of inspired oxygen (FiO2). Timepoint: before and after intervention. Method of measurement: ventilator.;Oxygen saturation. Timepoint: before and after intervention. Method of measurement: ventilator.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie vitamin A's effect on SARS-CoV-2 viral replication and immune response modulation?
How does vitamin A supplementation compare to standard-of-care treatments for acute respiratory symptoms in COVID-19 patients?
Are there specific biomarkers that predict response to vitamin A therapy in IRCT20200405046951N1 trial participants?
What are the potential adverse events associated with high-dose vitamin A in hospitalized COVID-19 patients?
How does vitamin A's anti-inflammatory properties synergize with other immune modulators in treating severe COVID-19?